- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ibrutinib for B cell malignancies ; volume:3 ; number:1 ; day:28 ; month:1 ; year:2014 ; pages:1-7 ; date:12.2014
Experimental hematology & oncology ; 3, Heft 1 (28.1.2014), 1-7, 12.2014
- Creator
-
Novero, Aileen
Ravella, Pavan M.
Chen, Yamei
Dous, George
Liu, Delong
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/2162-3619-3-4
- URN
-
urn:nbn:de:101:1-2021082920351495870065
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
02.09.2028, 12:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Novero, Aileen
- Ravella, Pavan M.
- Chen, Yamei
- Dous, George
- Liu, Delong
- SpringerLink (Online service)
Other Objects (12)
Drug Review: Ibrutinib
Extrahepatic metabolism of ibrutinib
Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie
Targeting CD22 for B-cell hematologic malignancies
Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients
Ibrutinib in B-cell lymphoma: single fighter might be enough?
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
Ibrutinib: Nutzenbewertung gemäß § 35a SGB V
Special issue: CAR‐T cell therapy for hematological malignancies
Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner
Drug Review: Ibrutinib
Extrahepatic metabolism of ibrutinib
Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie
Targeting CD22 for B-cell hematologic malignancies
Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients
Ibrutinib in B-cell lymphoma: single fighter might be enough?
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
Ibrutinib: Nutzenbewertung gemäß § 35a SGB V
Special issue: CAR‐T cell therapy for hematological malignancies
Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner
Drug Review: Ibrutinib
Extrahepatic metabolism of ibrutinib
Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie
Targeting CD22 for B-cell hematologic malignancies
Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients
Ibrutinib in B-cell lymphoma: single fighter might be enough?
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
Ibrutinib: Nutzenbewertung gemäß § 35a SGB V
Special issue: CAR‐T cell therapy for hematological malignancies